Emirates Pharma approves Jascaid for fibrosis

The Emirates Pharmaceuticals Authority has approved the use of the drug "Jascaid" for the treatment of idiopathic pulmonary fibrosis and progressive pulmonary fibrosis in adults, following a comprehensive evaluation of its effectiveness and safety based on clinical trial results. "Jascaid" is the first of its kind in the region to be approved in the country, and it helps slow the decline of lung function, reflecting the competency of the national regulatory system in approving pharmaceutical innovations.

articleDetails.fontSize.sizeحجم النص

تنويه: هذا ملخص تم إنشاؤه بواسطة الذكاء الاصطناعي

عرض المقال بالكامل